Format

Send to

Choose Destination
Mol Med. 2008 Jul-Aug;14(7-8):451-64. doi: 10.2119/2007-00100.Irvine.

Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases.

Author information

1
School of Medicine and Dentistry, The Queen's University of Belfast, Belfast, Northern Ireland. b.irvine@qub.ac.uk

Abstract

Developing effective treatments for neurodegenerative diseases is one of the greatest medical challenges of the 21st century. Although many of these clinical entities have been recognized for more than a hundred years, it is only during the past twenty years that the molecular events that precipitate disease have begun to be understood. Protein aggregation is a common feature of many neurodegenerative diseases, and it is assumed that the aggregation process plays a central role in pathogenesis. In this process, one molecule (monomer) of a soluble protein interacts with other monomers of the same protein to form dimers, oligomers, and polymers. Conformation changes in three-dimensional structure of the protein, especially the formation of beta-strands, often accompany the process. Eventually, as the size of the aggregates increases, they may precipitate as insoluble amyloid fibrils, in which the structure is stabilized by the beta-strands interacting within a beta-sheet. In this review, we discuss this theme as it relates to the two most common neurodegenerative conditions-Alzheimer's and Parkinson's diseases.

PMID:
18368143
PMCID:
PMC2274891
DOI:
10.2119/2007-00100.Irvine
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Feinstein Institute Icon for PubMed Central
Loading ...
Support Center